Journal of the National Cancer Institute · 2026
Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Flores-Toro Joseph, Jagu Subhashini, Smith Malcolm, Shern John, Hawkins Douglas S, Mardis Elaine R, Rudzinski Erin, Alonzo Todd A, Beeles Thalia, Ramirez Nilsa, Thomas Diana L, Cottrell Catherine E, Parbhoo Kareesma, Janeway Katherine A, Leary Sarah, Fouladi Maryam, Oberoi Sapna, Venkatramani Rajkumar, Irwin Meredith, Laetsch Theodore W, Chen Kenneth S, Bailey Kelly, Davis Jessica L, Sullivan Mary Beth, Boja Emily, Lowy Douglas, Guidry Auvil Jaime M, Wideman Brigitte, Kibbe Warren, Doroshow James, Reaman Gregory H
Аннотация
The Molecular Characterization Initiative (MCI), a key effort of the National Cancer Institute's Childhood Cancer Data Initiative (CCDI), was launched in 2022 in collaboration with the Children's Oncology Group (COG) to bring comprehensive genomic and molecular profiling to children, adolescents, and young adults diagnosed with cancer. The MCI provides paired tumor and germline molecular testing, with results returned to clinicians to inform care. Deidentified data are made available to the research community through the CCDI Data Ecosystem to facilitate the discovery of new treatment strategies. This commentary outlines the MCI's development, key accomplishments to date, and its role in laying the foundation for standardized clinical diagnostics in pediatric oncology.